stockrowZymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.
- Revenue
- −90.6%
- EPS
- −2,166.7%
- Free cash flow
- −385.5%
Quarter to June 2026, against a year earlier
Follow ZYME
Alert me
Zymeworks Inc. (ZYME) Current ratio
Zymeworks Inc.'s current ratio at the end of the quarter to 30 June 2026 was 6.3×, up 0.4× from fiscal 2025 (5.9×). Over the past ten years it has ranged from 2.8× (fiscal 2016) to 7.4× (fiscal 2023); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 5.9× | 72.75% |
| FY2024 | 3.4× | (54.05%) |
| FY2023 | 7.4× | 30.00% |
| FY2022 | 5.7× | 42.01% |
| FY2021 | 4.0× | (24.49%) |
| FY2020 | 5.3× | 40.63% |
| FY2019 | 3.8× | (44.58%) |
| FY2018 | 6.8× | 8.22% |
| FY2017 | 6.3× | 124.31% |
| FY2016 | 2.8× | (22.96%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 6.3× | (41.62%) |
| Mar 2026 | 10.8× | 84.04% |
| Dec 2025 | 5.9× | (15.28%) |
| Sep 2025 | 6.9× | (9.79%) |
| 36 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| COAG Hemab Therapeutics Holdings, Inc. compare | 35.8× |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 32.8× |
| IMNM Immunome, Inc. compare | 15.1× |
| VERA Vera Therapeutics, Inc. compare | 10.9× |
| ZYME Zymeworks Inc. | 6.3× |
| AUPH Aurinia Pharmaceuticals Inc compare | 6.1× |
| VCEL Vericel Corporation compare | 5.1× |
| SEPN Septerna, Inc. compare | 5.0× |
| BHVN Biohaven Ltd. compare | 3.1× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on ZYME
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement